On Monday, surgeons at Beijing Tiantan Hospital implanted the Beinao-1 brain-computer interface in a young man left paralysed after an electric scooter accident. The operation was livestreamed to hundreds of specialists who reviewed the surgical approach, electrode placement depth and signal debugging in real time.
Beinao-1 is a semi-invasive, wireless, fully implanted BCI developed by the Chinese Institute for Brain Research (CIBR) in Beijing and its spin-out NeuCyber NeuroTech. The system sits on the surface of the cortex through a small skull window and does not breach the dura mater, positioning it between the scalp-based EEG caps that dominated China’s earlier BCI efforts and the fully penetrating electrode arrays used by Neuralink and Paradromics in the United States. CIBR director Luo Minmin co-leads the programme.
The flexible electrode array records from 128 channels — a figure CIBR has described as a global record for a semi-invasive implant of this class. In previous cohorts the system has decoded motor intent and roughly a hundred common Chinese words, and has been used by a patient with amyotrophic lateral sclerosis to produce speech output and by others to operate a robotic arm and a computer cursor.
The patient implanted on Monday is expected to begin hand-function training with closed-loop BCI feedback two weeks after surgery. According to recent statements from the programme, seven patients had been implanted before this week’s procedure; CIBR has said it plans to complete 13 investigator-initiated implants during 2026 before moving to a formal clinical trial of around 50 patients once regulatory approval is in place.
The livestream itself is the headline. Chinese BCI work has moved quickly over the past twelve months but has largely been reported through brief official statements, state broadcaster segments and conference demonstrations. Opening the surgery to a wider audience of neurosurgeons and investigators — and allowing them to interrogate implantation depth and signal handling as it happened — is the kind of visibility that US and European BCI companies have generally reserved for trial readouts rather than the operating theatre.
The commercial backdrop reinforces why Beinao-1 is watched closely outside China. Hubei province earlier this year set a reimbursement benchmark of 6,552 yuan — roughly US$900 — for an invasive BCI implant procedure, with removal priced at 3,139 yuan. That is a fraction of what an equivalent procedure would cost in the US private market, and it lands at a moment when Beijing has added BCIs to the national government work report as a strategic industry. A Beinao-2 system using a different technical architecture is in preclinical work and has been previewed at the Zhongguancun Forum, with clinical verification targeted for this year.
Read alongside Neuralink’s twentieth implant milestone and Paradromics’ move into its Connexus speech trial, the Tiantan livestream signals a second front in the race to commercialise high-channel-count cortical recording. Beinao-1 reaches fewer channels than a fully penetrating array and trades some signal resolution for a lower-trauma profile — but it is already implanted in more patients than most Western programmes, on a cost structure designed for public reimbursement.
If the formal trial starts on schedule later this year, China will be running the first sizeable commercial BCI cohort outside the US at a price point its competitors are not yet positioned to match.